ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch - Seite 3

View source version on businesswire.com: https://www.businesswire.com/news/home/20250407918834/en/

The ImmunityBio Stock at the time of publication of the news with a fall of -5,71 % to 2,443USD on Tradegate stock exchange (07. April 2025, 10:42 Uhr).